Although debates still exist whether Helicobacter pylori infection is really class I carcinogen or not, H. pylori has been known to provoke precancerous lesions like gastric adenoma and chronic atrophic gastritis with intestinal metaplasia as well as gastric cancer. Chronic persistent, uncontrolled gastric inflammations are possible basis for ensuing gastric carcinogenesis and H. pylori infection increased COX-2 expressions, which might be the one of the mechanisms leading to gastric cancer. To know the implication of long-term treatment of antiinflammatory drugs, rebamipide or nimesulide, on H. pylori-associated gastric carcinogenesis, we infected C57BL/6 mice with H. pylori, especially after MNU administration to promote carcinogenesis and the effects of the long-term administration of rebamipide or nimesulide were evaluated. C57BL/6 mice were sacrificed 50 weeks after H. pylori infection. Colonization rates of H. pylori, degree of gastric inflammation and other pathological changes including atrophic gastritis and metaplasia, serum levels and mRNA transcripts of various mouse cytokines and chemokines, and NF-κB binding activities, and finally the presence of gastric adenocarcinoma were compared between H. pylori infected group (HP), and H. pylori infected group administered with long-term rebamipide containing pellet diets (HPR) or nimesulide mixed pellets (HPN). Gastric mucosal expressions of ICAM-1, HCAM, MMP, and transcriptional regulations of NF-κB binding were all significantly decreased in HPR group than in HP group. Multi-probe RNase protection assay showed the significantly decreased mRNA levels of apoptosis related genes and various cytokines genes like IFN-γ, RANTES, TNF-α, TNFR p75, IL-1β in HPR group. In the experiment designed to provoke gastric cancer through MNU treatment with H. pylori infection, the incidence of gastric carcinoma was not changed between HP and HPR group, but significantly decreased in HPN group, suggesting the chemoprevention of H. pylori-associated gastric carcinogenesis by COX-2 inhibition. Long-term administration of antiinflammatory drugs should be considered in the treatment of H. pylori since they showed the molecular and biologic advantages with possible chemopreventive effect against H. pylori-associated gastric carcinogenesis. If the final concrete proof showing the causal relationship between H. pylori infection and gastric carcinogenesis could be obtained, that will shed new light on chemoprevention of gastric cancer, that is, that gastric cancer could be prevented through either the eradication of H. pylori or lessening the inflammation provoked by H. pylori infection in high risk group.
contact with gastric epithelial cells (through type IV secretory system) and stimulation of various cytokine releases (Yamaoka et al., 1996; Go, 1997) , based on the fact that gastric epithelia from H. pylori-infected persons demonstrate enhanced levels of interleukin-1β (IL-1β), IL-2, , and tumor necrosis factor-α (TNF-α) (Yoshida, 1993; Moss et al., 1994) .
Another consequence of persistent inflammation may be alterations in cellular turnover. Gastric epithelial cell proliferation rates within colonized mucosa are significantly increased compared to those in uninfected controls (Bechi et al., 1996) . In chronic H. pylori infection, there is a notable lack of epithelial cell necrosis, suggesting that other forms of cellular demise such as apoptosis may be induced (Peek et al., 1997) . Although substantial variation exists among apoptosis scores in H. pylori infection, several studies have reported increased levels of gastric epithelial cell apoptosis among H. pylori-infected persons (Moss et al., 1996) . H. pylori-induced gastritis may also lead to other forms of epithelial cell injury and damage. Activated neutrophils generate reactive oxygen or nitrogen species that can induce oxidative DNA damage via formation of DNA adducts (Rautelin et al., 1994; Zhang, 1996) . Upon contact with H. pylori in vitro, an oxidative burst occurs within polymorphonuclear cells. The specific types of cellular damage resulting from generation of reactive oxygen species include lipid peroxidation, protein oxidation, and oxidation of DNA (Baik et al., 1996) . All these mechanisms were principally involved in mucosal cell damages by H. pylori and some of these actions might be involved in H. pylori-associated gastric carcinogenesis. Therefore, some modifying trials will be needed to reduce the harmful injuries by H. pylori infection. The eradication of H. pylori infection itself or administration of blockers like NSAIDs or other antiinflammatory drugs will be the next candidate.
Nimesulide is one of the preferred inhibitor of cyclooxygenase-2 (COX-2) prescribed for anti-inflammation and pain relief (Davis et al., 1994) . Several studies suggested these NSAIDs shed the possiblity of chemoprevention in colon carcinogenesis and preventing the development of colon adenoma or polyps (Reddy, 1996; Jacoby et al., 2000) . Since COX-2 is highly expressed and induced in H. pylori infection and the attenuation of its expression was noted after the eradication of H. pylori (Sung et al., 2000) , COX-2 inhibitor will be also one of the candidate for potential chemopreventive agent in H. pylori-associated gastric carcinogenesis (Fig. 1) . Rebamipide has been reported to improve H. pylori-associated gastritis through either removing active oxygen species, scavenger of active oxygen species, or attenuating the productions of cytokines/chemokines (Yoshida, 1996; Arakawa et al., 1998) . Until now although there have been several reports to document the effects and mechanisms of rebamipide in H. pylori-associated gastritis Fig. 1 . Involvement of COX-2 in the various stages of H. pylori infection, providing insights about chemoprevention through the reduction of COX-2. H. pylori infection provoked superficial gastritis, atrophic gastritis, gastric dysplasia, and even gastric carcinoma, which led to the WHO's definition H. pylori as a class I carcinogen (1994 IARC, Lyon, France). The odd ratio of risk of gastric cancer by the H. pylori infection is 2-8. Interestingly, the H. pylori infection induced COX-2 expressions. Since COX-2 is largely regarded as responsible for tumorigenesis, the modulation of COX-2 levels or other inflammatory mediators might be intervening in the chemoprevention of the H. pylori-associated gastric carcinogenesis. and peptic ulcer disease (Yamasaki et al., 1987; Han, 1995) , all these were done on designated periods of administration. Therefore, none was reported about the ex vivo effects of longterm administration of rebamipide or COX-2 inhibitors on H. pylori-associated gastritis. Recently we did do animal experiment to document the chemopreventive activities of anti-inflammatory drugs on H. pylori-associated gastric carcinogenesis, which will appear in the following section. Protocol for the study. Out of a total of 220 C57BL/6 mice, 180 mice were divided into 6 groups of 30 mice in each group (Groups 3 and 6 allocated 40 mice per group, due to the relatively low colonization rate of H. pylori than the other groups). They were given MNU that was mixed in their drinking water at concentrations of 200 ppm (Groups 4-7) for a total of five cycles of one-week regimens with a one-week pause. After completion of the MNU administration, they were given autoclaved distilled water for two weeks. Groups 4, 6, and 7 were further inoculated with H. pylori three times every other day. H. pylori was given to mice without prior MNU treatment (Groups 2 and 3). The remaining 20 mice were given only distilled water, without H. pylori or MNU as noncarcinogen controls (Group 1). 
Experiments Performed to
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Effect of the long-term administration of nimesulide or rebamipide on tumor incidence of mice The survival rate of each group was more than 85% and all animals in Group 3 survived until the 50th week (Table 1 ). The incidence of gastric tumors at the 50th week was 64.7%, 10.5%, 61.1%, and 38.9% in Group 4, Group 5, Group 6, and Group 7, respectively, suggesting the significantly higher incidence of gastric tumors in mice treated with the combination of MNU and H. pylori infection and significantly lower incidence of gastric tumors in group co-treated with nimesulide. These results signified that H. pylori infection surely promoted MNU-induced gastric carcinogenesis and these promoting effect was abolished by COX-2 inhibitor. H. pylori alone (Group 2) Fig. 4 showed the NF-κB complex of nuclear proteins extracted from each group detected by electrophoretic mobility shift assay. The nuclear proteins were extracted from the three randomly selected mice stomach of each group, suggesting the EMSA band as the mean activities of each group. H. pylori infection (lane 2) increased NF-κB-DNA binding significantly than non-infected group (lane 1). However, treatment of rebamipide decreased NF-κB binding significantly (16.6% of lane 2). In a point of NF-κB-DNA binding, administration of MNU only caused slight increment of NF-κB binding irrespective of H. pylori infection, but lane 6, group treated with rebamipide also attenuated the NF-κB binding than MNU and H. pylori group (lane 5), suggesting the possible actions of rebamipide on modulating the inflammatory response through transcriptional regulation of NF-κB.
Effects of the long-term administration of rebamipide on mRNA of cytokines and apoptosis-related genes
We investigated the various mRNA transcripts of mouse cytokines and chemokines by multi-probe RNase protection assay. 
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significant change was noted in MNU treated group irrespective of rebamipide administration. Fig. 5B showed the RPA of mCK-5 showing chemokines like Ltn, RANTES, Eotaxin, MIP-1β, MIP-1α, MIP-2, IP-10, MCP-1, TCA-3. Similar to cytokines, H. pylori infection increased all of these chemokines except MIP-2 and TCA-3. Long-term administration of rebamipide showed remarkable decreases in transcript levels of RANTES, Lin, and IP-10 in MNU treated group, rebamipide decreased RANTES, eotaxin, and MIP-1α. Fig. 6 showed the RPA of mAPO-3 containing caspase-8, FasL, Fas, FADD, FAP, FAF, TRAIL, TNFRp55, TRADD, RIP. H. pylori infection increased the genes involved in apoptosis. Slight decreases in transcript of caspase-8, FasL, Fas and TRAIL were observed in long-term administration of rebamipide pretreated with MNU.
Chemoprevention of Helicobacter pylori-associated Gastric Carcinogenesis in Mice Model; Is It Possible?
Our above described study showed nimesulide, preferred COX-2 inhibitor, resulted in significant decrease in H. pyloriassociated gastric carcinogenesis and rebamipide, anti-ulcer and anti-inflammatory drug, showed significant attenuating effects in the severity of H. pylori-associated gastritis, based on the findings that rebamipide decreased cell adhesion molecule, ICAM-1 and HCAM, reduced MMP activities, decreased COX-2 expressions, reduced the DNA binding of inflammation-associated transcription factor, NF-κB, decreased cytokine activities like IL-1β, TNF-α, RANTES, IP-10, MIP-1α, and IFN-γ.
Long-term administration of nimesulide showed significant strong chemopreventive actions against H. pylori-associated gastric carcinogenesis and halted the progress from gastric adenoma to gastric cancer. These results might be ensuied from the blockade of COX-2 in the progression of adenomatous growth. Whereas, the long-term administration of rebamipide did not show the definite evidence of chemoprevention in spite of excellent anti-inflammatory action, which could be explained by the fact that rebamipide maintained the balance between cell proliferation and apoptosis, since apoptosis must exceed cell proliferation in order to achieve chemoprevention (Moss, 1998) . However, the development of precancerous lesion like chronic atrophic gastritis was surely retarded and decreased by the long-term The study described in the above section might be the first study showing the chemoprevention of nimesulide or rebamipide in H. pylori-infected animal model (Fig. 7) . Before this, there was rat model with chronic gastritis developed by the continuous administration of 5mM sodium taurocholate for six months. Rebamipide treatment for four weeks (6 and 60mg/kg/day) initiated after development of chronic gastritis dose-dependently attenuates the gastritis in terms of degree of inflammatory cell infiltration, erosions, and glandular atrophy (Kishimoto, 1992) . Proposed mechanisms for anti-inflammatory and mucosal protective actions of rebamipide were decreased neutrophilic activitity (Suzuki et al., 1994) , decreased production of inflammatory cytokines (Aihara et al., 1998) , and decreased generations of oxygen free radicals (Iinuma et al., 1998) . Chemoprevention by NSAIDs was only tried in familial adenomatous polyposis and colon cancer model. Chemoprevention trials in gastric carcinogenesis and even H. pylori-association were not reported at all before the current trial except in vitro evidence of retinoic acids in the cytotoxicity of gastric cancer cells. Recently Steinbach et al. (2000) reported the definite advantage of celecoxib, a specific COX-2 inhibitor, in preventing the development of colonic adenomatous polyposis in familial adenomatosis polyposis patients. The exact underlying molecular mechanisms how nimesulide showed the significant chemopreventive actions are under investigation. Instead, in the current study, data about the molecular actions of another antiinflammatory drug used in the current study, rebamipide, were revealed.
Since H. pylori generally adhered to gastric epithelial cells without invading the epithelium, it is presumed that an interaction between bacteria and host epithelia cells may initiate H. pylori-induced inflammation (Ernst et al., 1997) . Because of the strong inflammatory response to H. pylori infections, the role of inflammatory cytokines has been investigated and it was shown that mucosal biopsy specimens from patients with H. pylori infection contain significantly elevated levels of IL-1β, IL-6, TNF-α, and IL-8 compared to those in specimens from uninfected individuals (Crabtree, 1991; Rieder et al., 1997; Yamaoka et al., 2001) . Most intracellular bacteria generally induce Th1 responses, while extracellular pathogens stimulate Th2 responses. Based on the fact that H. pylori are non-invasive and that infection is accompanied by an exuberant humoral response, one might predict that a Th2 response would be predominant within H. pylori-colonized gastric mucosa. Paradoxically, the majority of H. pylori antigen-specific T-cell clones isolated from infected gastric mucosa produce higher levels of IFN-γ than IL-4 or IL-10, which is reflective of a Th1 type response (Bamford et al., 1998) . Therefore, certain strains of mice (C57BL/6) infected with H. felis that develop a Th1 type )LJ (IIHFWV RI ORQJWHUP DGPLQLVWUDWLRQ RI UHEDPLSLGH RQ P51$ RI DSRSWRVLVUHODWHG JHQHV 53$ RI P$32 5LER4XDQW &DW S GHDOW ZLWK FDVSDVH )DV/ )DV )$'' )$3 )$) 75$,/ 71)5S 75$'' DQG 5,3 7KH + S\ORUL LQIHFWLRQ LQFUHDVHG WKH JHQHV WKDW ZHUH LQYROYHG LQ DSRSWRVLV 6OLJKW GHFUHDVHV LQ WKH WUDQVFULSW RI FDVSDVH )DV/ )DV DQG 75$,/ ZHUH REVHUYHG LQ WKH ORQJWHUP DGPLQLVWUDWLRQ RI UHEDPLSLGH WKDW ZDV SUHWUHDWHG ZLWK 018 /DQH 1RUPDO FRQWURO /DQH + S\ORUL DORQH /DQH + S\ORUL UHEDPLSLGH/DQH018DORQH/DQH018+ S\ORUL/DQH018 + S\ORULUHEDPLSLGH response exhibit extensive gastric inflammation, while other genetically distinct strains (BALB/c) that respond to infection with a Th2-like response develop only minimal gastritis (Sakagami et al., 1996) . Adoptive transfer of Th2 lymphocytes from infected mice into infected recipients reduces bacterial colonization density, while transfer of Th1 cells increases the severity of gastritis (Mohammadi et al., 1997) . In the current experiment, we could confirm that definite Th1 type response was generated by H. pylori infection and long-term administration of rebamipide, antiinflammatory drug, attenuated Th1 type cytokine generations and increased Th2 type cytokine, which led to decreased gastric inflammation in final.
Cell-cell interactions play an important and probably central role in a large number of immunological processes in physiological and pathological conditions. These interactions are at least partially mediated by various cell adhesion molecules. Expression of cell adhesion molecules on gastric epithelial cells may participate in leukocyte homing and epithelial cell adhesions in H. pylori-associated mucosal inflammations (Mori et al., 2000) . In the context of H. pylori infection, the production of chemoattractive cytokines and cell adhesion molecules could provide a means of recruiting and retaining inflammatory cells within gastric epithelial cells, contributing to H. pylori-mediated tissue injury. Co-culture of epithelial cells with cytotoxin-associated gene pathogenicity island-positive (cag PAI+) H. pylori strains, but not with a cag PAI-strain resulted in up-regulation of steady-state mRNA levels and cell surface expressions of ICAM-1. H. pylori activated the ICAM-1 or IL-8 promoter via the NF-κB binding site (Keates et al., 1997) . In the current study, longterm administration of rebamipide showed the advantage of decreasing ICAM-1 and even HCAM.
The finding that H. pylori is a potent activator of NF-κB has important implications, since other NF-κB responsive genes, including those encoding IL-8, TNF-α, IL-1, and IL-6, has been found to be elevated in the gastric mucosa of persons with H. pylori (Crabtree et al., 1991; Sakagami et al., 1996; Ernst et al., 1997; Keates et al., 1997; Mohammadi et al., 1997; Rieder et al., 1997; Aihara et al., 1998; Bamford et al., 1998; Iinuma et al., 1998; Sharma, 1998; Mari et al., 2000; Yamaoka et al., 2001) . NF-κB is well recognized as a redoxsensitive transcription factor and has been implicated in the cellular response to oxidative stress. Nearly all the inflammatory pathways leading to NF-κB activation could be blocked by a variety of antioxidants, including N-acetyl-Lcystein, glutathione, thioredoxin, pyrrolidine dithiocarbamate or by over-expression of antioxidant enzymes (Schreck, 1992; Mckay et al., 1999) . H. pylori-induced NF-κB activation and the subsequent up-regulation of cytokines could contribute to inflammatory cell recruitment and retention at sites of infection. Because of its pivotal role in inflammation, NF-κB will be an obvious target for new types of anti-inflammatory treatments for H. pylori-induced gastritis (Mori et al., 2000) . In the current experiment, long-term administration of rebamipide in H. pylori infection significantly attenuated the participation of NF-κB-DNA binding, which resulted in reducing the cytokines involved in H. pylori-associated gastric inflammation.
H. pylori infection is associated with elevated levels of both mucosal apoptosis and proliferation. The initiation and the regulation of the pathways that promote these paradoxical pylori infection after the MNU administration, the pathologies remained as chronic atrophic or hypertrophic gastritis as far as the lifespan of mice. Nimesulide administration blocked the progression of gastric adenoma to gastric adenocarcinoma, and rebamipide administration decreased the development of precanceous lesions like chronic atrophic gastritis in mice. Photography (×100 magnification) cellular responses are still unclear. However, the any disturbances in maintaining this homeostasis between apoptosis and proliferation could result in definite clinical outcome like peptic ulcer disease or gastric cancer (Asaka, 1998; Moss, 1998; Konturek et al., 2001) . Fas Ag, which is a transmembrane receptor, which when bound specifically to its ligand (FasL) trimerizes and initiates a cascade of events resulting in apoptosis. By the way, Fas Ag and Fas L expression had been shown to be regulated at the mRNA level in H. pylori-induced gastritis by inflammatory cytokines such as IL-1β, TNF-α, and IFN-γ (Jones et al., 1999) .
Although there have been several reports showing the increased mucosal inflammatory cytokines, including IL-1β, IL-6, IL-8, TNF-α, and IFN-γ in cells or human tissue homogenates of H. pylori-associated gastritis (Peek et al., 1995) , current study might be the first report revealing the real evidence of the activation of these genes in mouse model of H. pylori infection and the attenuation of these cytokines by the long-term administration of anti-inflammatory and radical scavenging drug, rebamipide. According to RNase protection assay of current study, surely H. pylori infection increased apoptosis-related genes, caspase-8, Fas Ag, Fas L, FAF, and TRADD, but there were no definite changes of apoptosisrelated genes by rebamipide treatment. In mice model of MNU and H. pylori administration, rebamipide reduced Fas L and Fas mRNA. We inferred that failure of definite chemopreventive effect of rebamipide could be explained by the maintenance of cell proliferation in spite of long-term rebamipide administration, suggesting the requirement of another apoptosis inducing drug to achieve chemopreventive effect of rebamipide. According to the report by Wang et al. (2000) , gastric T cells contribute to apoptosis of the epithelium by a Fas/FasL interaction, which was increasingly expressed during infection with H. pylori. In the current experiment, clear decrement of Fas/FasL mRNA was observed in rebamipide administration, but this result was from the total RNA extracted of whole gastric mucosal scratches, not of mucosal T cells.
The natural history of H. pylori-associated gastritis is an inexorable progression involving more and more of the stomach, ultimately leading to gastric atrophy (Go, 2000) . In general, this process is slow, requiring between 20 and 40 years to complete (Uemura et al., 2001) . Atrophic gastritis is widely considered to be a precursor lesion of the intestinal type of gastric cancer (Asaka et al., 1997) . A multi-step model for the development of gastric cancer has been proposed beginning with a histological diagnosis of superficial gastritis, which then progressed to chronic atrophic gastritis, followed by intestinal metaplasia, and ultimately, dysplasia (Correa, 1995) . In the study shown above, long-term administration of nimesulide or rebamipide resulted in reduced development of chronic atrophic gastritis compared to non-treated group. Although long-term rebamipide administration did not achieve the reduction of gastric carcinogenesis developed by H. pyloris promoting carcinogenesis of MNU administration, significant reduction in the expression of MDM-2, "big brother" of p53 (Momand et al., 1996) , and ODC, accelerator for cell growth (Mori et al., 1996) and significant elevation of pS2/TFF1, possible tumor suppressor protein (Lefebvre et al., 1996) , were reached, suggesting the potential implication of rebamipide should be considered as ultimate chemoprevention protocol for gastric carcinogenesis. 
The Perspective of Chemoprevention of H. pylori-associated Gastric Carcinogenesis
Many evidences suggest that H. pylori surely caused gastric malignancies including adenocarcinoma and lymphoma (Uemura et al., 2001) . H. pylori provoked acute and chronic gastritis, chronic atrophic gastritis, and gastric adenoma, by which WHO-IARC defined H. pylori as class I carcinogen. By the way, since H. pylori can be removed by medications composing of one or two weeks of triple drug regimen including proton pump inhibitor and antibiotics, chemoprevention of gastric carcinoma could be possible, if we can definitely confirm the mechanistic links between H. pylori infection and gastric cancer. Although our current trial that the long-term administration of anti-inflammatory drugs, nimesulide or rebamipide, showed either the excellent antiinflammatory effects and partial anti-proliferative effects or definite chemopreventive effects in H. pylori infection, but further clinical trials will be required to draw the definite clinical advantage of the longterm administration of antiinflammatory drugs, nimesulide or rebamipide or both (Fig. 8) 
